Form 8-K - Current report:
SEC Accession No. 0001493152-24-021143
Filing Date
2024-05-23
Accepted
2024-05-23 16:05:25
Documents
15
Period of Report
2024-05-21
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43972
2 ex3-1.htm EX-3.1 343680
3 ex3-2.htm EX-3.2 400599
  Complete submission text file 0001493152-24-021143.txt   1127222

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE mymd-20240521.xsd EX-101.SCH 3003
5 XBRL LABEL FILE mymd-20240521_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE mymd-20240521_pre.xml EX-101.PRE 22351
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3957
Mailing Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205 856-848-8698
MyMD Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36268 | Film No.: 24978139
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)